Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Welcome to the First Annual Issue of HOPA Abstracts, 2021

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Director, Pharmacy Cancer Care, and Assistant Professor of Pharmacy, Mayo Clinic, Rochester, MN; HOPA Past President, 2016-2017

Welcome to the special issue of the Journal of Hematology Oncology Pharmacy (JHOP), the official publisher of the Hematology Oncology Pharmacy Association (HOPA). This special issue represents the First Annual Issue of HOPA Abstracts, 2021, and features a selection of the abstracts presented at the 17th Annual Conference of HOPA.

The abstracts featured in this issue were selected through a peer review by the HOPA Review Committee among the more than 300 abstracts that were presented at the 2021 HOPA Annual Conference on April 13-17, 2021. Because of the current pandemic restrictions, this year’s annual conference was held as a virtual meeting.

Formed in 2004, HOPA is a nonprofit, education-based organization created to help hematology oncology pharmacy practitioners and their associates to provide the best possible cancer care. HOPA’s 2004 mission statement was “to reduce the burden of cancer on society and promote optimal, cost-effective care for those affected by cancer.”

Today, HOPA supports hematology oncology research, provides education, encourages the professional development of hematology oncology pharmacists, and advocates for health policy issues that aim to improve patient care.

Currently totaling more than 3000 members, HOPA serves members in the fields of hematology oncology pharmacy, pharmacy administration, and research, and includes pharmacists, pharmacy residents, interns, and technicians specializing in hematology oncology practice.

HOPA’s mission is to support hematology oncology pharmacy practitioners and promote and advance hematology oncology pharmacy to optimize the care of individuals affected by cancer. The overarching goal of the organization is to ensure that every patient affected by cancer can have a hematology oncology pharmacist on their care team to optimize the medical care they receive.

The 20 abstracts featured in this special issue represent a sample of the hard work of pharmacists, researchers, residents, and pharmacy students in the United States and across the globe in the areas of clinical research, translational science, quality improvement, and practice management—all focused on the delivery of optimal care for the individual patient with cancer.

Related Items
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.